



28. Ivkovic J, Lindsten A, George V, et al. Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia. *J Clin Psychopharmacol* 2019; 39: 13–19.
29. Forbes A, Hobart M, Ouyang J, et al. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia. *Int J Neuropsychopharmacol* 2018; 21: 433–441.
30. Newcomer JW, Eriksson H, Zhang P, et al. Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies. *Curr Med Res Opin* 2018; 34: 2197–2205.
31. Otsuka America Pharmaceutical I. Data on file (REX-024). Safety Profile for REXULTI® (brexpiprazole) as Adjunctive Treatment in MDD, 2018. [cited 2019 Jan 14]. Available from: <https://www.rexultihcp.com/mdd/safety>
32. Markovic M, Gallipani A, Patel KH, et al. Brexpiprazole. *Ann Pharmacother* 2017; 51: 315–322.
33. Diefenderfer LA, Iuppa C: Brexpiprazole. A review of a new treatment option for schi-

zophrenia and major depressive disorder. *Ment Health Clin* 2017; 7: 207–212.

34. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. *JAMA Intern Med* 2014; 174: 1930–1933.

35. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry* 2018; 51: 9–62.

36. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? *Int J Clin Pract* 2015; 69: 978–997.

37. Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. *Ther Adv Psychopharmacol* 2017; 7: 29–41.